Targeting the MDM2-p53 interaction as a therapeutic strategy for the treatment of cancer

Cell Health and Cytoskeleton

Volumn 2, Issue 1, 2010, Pages 49-58

  Peirce, Susan K ^a   Findley, Harry W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MDM2; MDMX; Nutlin 3a; P53; TAp73

Indexed keywords

EID: 78449232165     PISSN: None     EISSN: 11791330     Source Type: Journal    
DOI: 10.2147/chc.s4952     Document Type: Review

References (96)

1. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A. 1979;76(5):2420-2424.
2. Lane DP, Crawford LV. T antigen is bound to a host protein in SY40- transformed cells. Nature. 1979;278(5701):261-263.
3. Linzer DIH, Levine AJ. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979;17(1):43-52.
4. Levine AJ, Finlay CA, Hinds PW. p53 is a tumor suppressor gene. Cell. 2004;116(S 2):S67-S70.
5. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083-1093.
6. Oren M, Levine AJ. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natil Acad Sci U S A. 1983;80(1): 56-59.
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
8. Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107.
9. Iwakuma T, Lozano G. MDM2, An Introduction. Mol Cancer Res. 2003;1(14):993-1000.
10. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237-1245.
11. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55(1):96-107.
12. Haupt Y, Maya R, Kazaz A, Oren M. MDM2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296-299.
13. Wu X, Bayle JH, Olson D, Levine AJ. The p53-MDM-2 autoregulatory feedback loop. Genes Dev. 1993;7(7a):1126-1132.
14. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer. 2009;9(10):738-748.
15. Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2 Oncogene in Leukemia and Lymphoma. Leuk Lymphoma. 1996;21(5):391-397.
16. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene. 2007;26(9): 1317-1323.
17. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates HDM2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A. 2003;100(21): 12009-12014.
18. Bianco R, Ciardiello F, Tortora G. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets. 2005;5(1):51-56.
19. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008;14(17):5318-5324.
20. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23-31.
21. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-216.
22. Carr J, Bell E, Pearson ADJ, et al. Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse. Cancer Res. 2006;66(4):2138-2145.
23. Carr-Wilkinson J, O'Toole K, Wood KM, et al. High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clinl Cancer Res. 2010;16(4):1108-1118.
24. Tweddle D, Pearson A, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003;197(1-2):93-98.
25. Kim E, Shohet J. Targeted molecular therapy for neuroblastoma: The ARF/MDM2/p53 axis. J Natl Cancer Inst. 2009;101(22): 1527-1529.
26. Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006;5(9):2358-2365.
27. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-331.
28. Shimizu H, Hupp TR. Intrasteric regulation of MDM2. Trends Biochem Sci. 2003;28(7):346-349.
29. Banin S, Moyal L, Shieh S-Y, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281(5383): 1674-1677.
30. Gonzalez S, Prives C, Cordon-Cardo C. p73{alpha} Regulation by Chk1 in response to DNA damage. Mol Cell Biol. 2003;23(22): 8161-8171.
31. Kruse J-P, Gu W. Modes of p53 regulation. Cell. 2009;137(4): 609-622.
32. Liang S-H, Clarke MF. Regulation of p53 localization. Eur J Biochem. 2001;268(10):2779-2783.
33. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6(9):663-673.
34. Uo T, Kinoshita Y, Morrison RS. Apoptotic actions of p53 require transcriptional activation of PUMA and do not involve a direct mitochondrial/ cytoplasmic site of action in postnatal cortical neurons. J Neurosci. 2007;27(45):12198-12210.
35. Taylor W, Stark G. Regulation of the G2/M transition by p53. Oncogene. 2001;20(15):1803-1815.
36. Brummelkamp T, Fabius A, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability. Nat Chem Biol. 2006;2:202-206.
37. Vincenzo L, Gerry M. Evolution of functions within the p53/p63/p73 Family. Ann N Y Acad Sci. 2000;926: 90-100.
38. Tang Y, Zhao W, Chen Y, Zhao Y, Gul W. Acetylation is indispensable for p53 activation. Cell. 2008;133(4):612-626.
39. Costanzo A, Merlo P, Pediconi N, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Molecular Cell. 2002;9(1):175-186.
40. Ramadan S, Terrinoni A, Catani MV, et al. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun. 2005;331(3): 713-717.
41. Hori T, Kondo T, Kanamori M, et al. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 2010;287(1):98-108.
42. Marchenko N, Moll U. The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle. 2007;6:1718-1723.
43. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001;20(30):4041.
44. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. D 1998; 95(26): 15608-15612.
45. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain. Science. 1996;274(5289):948-953.
46. Chan WM, Mak MC, Fung TK, Lau A, Siu WY, Poon RYC. Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res. 2006;4(1):15-25.
47. Allende-Vega N, Saville MK, Meek DW. Transcription factor TAFII250 promotes Mdm2-dependent turnover of p53. Oncogene. 2007;26(29):4234-4242.
48. Feng J, Tamaskovic R, Yang Z, et al. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem. 2004;279(34):35510-35517.
49. Goldberg Z, Sionov RV, Berger M, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 2002;21(14):3715-3727.
50. Mayo LD, Seo YR, Jackson MW, et al. Phosphorylation of human p53 at Serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem. 2005;280(28):25953-25959.
51. Tang J, Qu L, Pang M, Yang X. Daxx is reciprocally regulated by Mdm2 and Hausp. Biochem Biophys Resh Commun. 2010;393(3):542-545.
52. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res. 2003;1(14):1017-1026.
53. Migliorini D, Lazzerini DE, Danovi D, et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol. 2002;22(15):5527-5538.
54. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005;5(1):3-8.
55. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005;65(5):1918-1924.
56. Hu B, Gilkes DM, Chen J. Efficient p53 Activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res. 2007;67(18):8810-8817.
57. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res. 2001;7(11):3613-3624.
58. Zhang R, Wang H, Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets. 2005;5(1): 43-49.
59. Buolamwini JK, Addo J, Kamath S, Patil S, Mason M, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets. 2005;5(1):57-68.
60. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008; 105(10):3933-3938.
61. Vassilev LT, Vu BT, Craves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848.
62. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci U S A. 2006;103(6):1888-1893.
63. Kumamoto K, Spillare EA, Fujita K, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 2008;68(9):3193-3203.
64. Maimets T, Neganova I, Armstrong L, Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene. 2008;27(40):5277-5287.
65. Elisa B, Federica C, Erika R, et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem. 2008;104(2):595-605.
66. Drakos E, Thomaides A, Medeiros LJ, et al. Inhibition of p53-murine double minute 2 interaction by nutlin-3a stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res. 2007;13(11):3380-3387.
67. Du W, Wu J, Walsh EM, Zhang Y, Chen CY, Xiao Z-XJ. Nutlin-3 affects expression and function of retinoblastoma protein. J Biol Chem. 2009;284(39):26315-26321.
68. Cam H, Griesmann H, Beitzinger M, et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell. 2006;10(4):281-293.
69. Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol. 2002;14(6):684-691.
70. La Thangue NB. The yin and yang of E2F-1: balancing life and death. Nat Cell Biol. 2003;5(7):587-589.
71. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol. 1997;17(10):5771-5783.
72. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonistinduced apoptosis in human tumor cell lines. Oncogene. 2008;27: 5305-5314.
73. Hao H, Dong Y, Bowling M, Gomez-Gutierrez J, Zhou HS, McMasters K. E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation. BMC Cancer. 2007;7(1):24.
74. Lee Y-M, Lim J-H, Chun Y-S, et al. nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1{alpha}. Carcinogenesis. 2009;30(10):1768-1775.
75. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1alpha and Mdm2 modulate p53 function. J Biol Chem. 2003;278(16): 13595-13598.
76. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Gene. 2002;18(2):90-95.
77. Lunghi P, Costanzo A, Mazzera L, Rizzoli V, Levrero M, Bonati A. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clini Cancer Res. 2009;15(21):6495-6502.
78. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3(4):387-402.
79. Stiewe T, Pützer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 2002;9(3):237-245.
80. Zaika AI, Slade N, Erster SH, et al. {Delta}Np73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002;196(6):765-780.
81. Dominguez G, Garcia JM, Pena C, et al. {Delta}TAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 2006; 24(5):805-815.
82. Rossi M, A ES, Alessandro T, Gerry M, Richard AK. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann N Y Acad Sci. 2004;1028:143-149.
83. Lau LMS, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene. 2007;27(17):997-1003.
84. Peirce S, Findley H. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncology. 2009;34(5):1395-1402.
85. Lau LMS, Wolter JK, Lau JTML, et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene. 2009;28(19):2024-2033.
86. Secchiero P, Zerbinati C, Melloni E, et al. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts. Neoplasia. 2007;9(10):853-861.
87. Becker K, Marchenko N, Maurice M, Moll U. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ. 2007;14(7):1350-1360.
88. Isaacs JS, Saito Si, Neckers LM. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J Biol Chem. 2001; 276(21):18497-18506.
89. Slack A, Lozano G, Shohet JM. MDM2 as MYCN transcriptional target: Implications for neuroblastoma pathogenesis. Cancer Letters. 2005;228(1-2):21-27.
90. Slack A, Shohet J. MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Cell Cycle. 2005;4(7):857-860.
91. Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res. 2007;67(6): 2448-2455.
92. Chen L MA, Wood KM, Cole M, et al. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle. 2007;6(21):2.
93. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006;66(19):9646-9655.
94. Michaelis M, Rothweiler F, Klassert D, et al. Reversal of P- glycoproteinmediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 2009;69(2):416-421.
95. Van Maerken T, Ferdinande L, Taildeman J, et al. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst. 2009;101(22):1562-1574.
96. De Laurenzi V, Raschellà G, Barcaroli D, et al. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J Biol Chem. 2000;275(20):15226-15231.